(IBDS) iShares iBonds Dec 2027 - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46435UAA97 • Target Maturity
IBDS: Corporate, Bonds, Investment-Grade, Fixed-Income, Securities
IBDS, or the iShares iBonds Dec 2027 Term Corporate ETF, is a fixed-income ETF designed to provide exposure to investment-grade corporate bonds maturing in 2027. The fund is structured as a target maturity ETF, meaning it will hold bonds until they mature, at which point the ETF will liquidate and return capital to investors. This unique structure makes it an attractive option for investors seeking predictable cash flows and return of principal, similar to holding individual bonds but with the diversification benefits of an ETF.
The ETF invests at least 80% of its assets in the component securities of its underlying index, which tracks U.S. dollar-denominated, investment-grade corporate bonds with maturities in 2027. By focusing on a specific maturity year, IBDS allows investors to manage interest rate risk more effectively, as the funds duration will decrease over time as it approaches its maturity date. This feature is particularly valuable for investors seeking to ladder their bond exposure or hedge against liability-driven investment strategies.
With an AUM of over $2.9 billion, IBDS is a sizeable fund, which typically translates to better liquidity and tighter bid-ask spreads for investors. The fund is listed on NYSE ARCA, a popular exchange for ETFs, ensuring accessibility for both institutional and retail investors. Its expense ratio is competitive within the target maturity ETF space, making it a cost-effective solution for those looking to allocate to high-quality corporate debt.
For fund managers and investors, IBDS offers a straightforward way to gain exposure to a diversified portfolio of corporate bonds without the complexity of selecting individual securities. The funds focus on investment-grade debt ensures a higher credit quality compared to junk bond ETFs, though it also means lower yields compared to lower-rated debt. As with any bond investment, changes in interest rates will impact the funds price before maturity, but the target maturity structure helps mitigate some of this risk over the long term.
Additional Sources for IBDS ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
IBDS ETF Overview
Market Cap in USD | 2,922m |
Category | Target Maturity |
TER | 0.10% |
IPO / Inception | 2017-09-12 |
IBDS ETF Ratings
Growth 5y | 24.2% |
Fundamental | - |
Dividend | 69.9% |
Rel. Strength Industry | -2.03 |
Analysts | - |
Fair Price Momentum | 23.48 USD |
Fair Price DCF | - |
IBDS Dividends
Dividend Yield 12m | 4.42% |
Yield on Cost 5y | 4.96% |
Annual Growth 5y | 7.44% |
Payout Consistency | 95.1% |
IBDS Growth Ratios
Growth Correlation 3m | 92.6% |
Growth Correlation 12m | 93.4% |
Growth Correlation 5y | -8% |
CAGR 5y | 2.51% |
CAGR/Max DD 5y | 0.17 |
Sharpe Ratio 12m | -1.86 |
Alpha | 1.65 |
Beta | 0.05 |
Volatility | 1.87% |
Current Volume | 430.5k |
Average Volume 20d | 547k |
As of March 14, 2025, the stock is trading at USD 24.08 with a total of 430,457 shares traded.
Over the past week, the price has changed by -0.12%, over one month by +0.70%, over three months by +1.24% and over the past year by +6.05%.
Neither. Based on ValueRay Analyses, iShares iBonds Dec 2027 is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 24.20 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IBDS as of March 2025 is 23.48. This means that IBDS is currently overvalued and has a potential downside of -2.49%.
iShares iBonds Dec 2027 has no consensus analysts rating.
According to ValueRays Forecast Model, IBDS iShares iBonds Dec 2027 will be worth about 25.4 in March 2026. The stock is currently trading at 24.08. This means that the stock has a potential upside of +5.32%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 25.4 | 5.3% |